Cedars-Sinai names a new CFO

Cedars-Sinai Health System has promoted David Wrigley to executive vice president and CFO, the California health system announced.

Wrigley succeeds Edward M. Prunchunas, who is retiring after 41 years with Cedars-Sinai. Wrigley will also serve as treasurer, as well as secretary of the finance and investment committees of the Cedars-Sinai Medical Center Board of Directors.

Wrigley originally joined Cedars-Sinai in 2014 as vice president of finance, leading initiatives for the health system’s financial operations and contributing toward growth. He currently serves as senior vice president of finance and CFO for Cedars-Sinai Medical Center and Huntington Health, where he develops unified systems for financial reporting and collaborations across the health system. 

In his new role, Wrigley will have broad oversight for financial planning and report, revenue cycle, treasury, financial operations, capital structure/planning, risk management, corporate compliance and new financial ventures.  

“David is a highly effective leader and a strong advocate for our health system and its employees," Thomas M. Priselac, president and CEO of Cedars-Sinai, said in a statement. "We are fortunate to have a leader of his caliber with deep knowledge of healthcare finance."

Prior to joining Cedars-Sinai, Wrigley served in several financial management positions, including leadership roles at the largest Catholic health system in Illinois. He also managed the healthcare practice at KPMG.

Cedars-Sinai is a nonprofit academic healthcare organization serving Southern California. Cedars-Sinai Medical Center in Los Angeles has been named one of the top hospitals in the United States for many years.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.